<?xml version="1.0" encoding="UTF-8"?>
<p id="p0125">A high rate of venous thromboembolism (VTE) has been noted in COVID-19, occurring in up to one-third of critically ill patients, despite prophylactic anticoagulation.
 <xref rid="bib51" ref-type="bibr">
  <sup>51</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib52" ref-type="bibr">
  <sup>52</sup>
 </xref> Because JAK inhibitors carry a “black box warning” of increased VTE risk, there is reasonable concern that their use may increase the likelihood or severity of VTE when used in patients with COVID-19.
 <xref rid="bib53" ref-type="bibr">
  <sup>53</sup>
 </xref>
</p>
